Thanks for the information, I saw that on Fox as well and the CEO was on CNBC with J Cramer did the 6 minutes interview. It is very informative about the potential of SGEN.
The biotech sector was volatile last Friday is due to options expiration--I guess.
Besides that, I am off-topic to talk a little bit about imuc.
According to the press release from the last quarter report, I can’t wait to see IMUC to announce the more mature data of ICT-107. I think that the manufacturing process for ICT-107 at phase 2 trial is different from the phase 1 trial (second generation manufacturing process).
I hope that the company will learn from the phase 2 trial and meet with the FDA to discuss the phase 3 trial for different patient selection and manufacturing process.
Here is what the CEO said: "We anticipate many important milestones in 2014. We have submitted an abstract for acceptance, and we are looking forward to presenting at ASCO the matured data set from the phase II trial of ICT-107 in patients with newly diagnosed glioblastoma, including updated efficacy data and predefined subset and immunological data that can help to define our clinical strategies for this program going forward. We are preparing to meet with the FDA in an end-of-phase-II meeting to discuss the protocol for a phase III trial with ICT-107”.
I was favorably impressed with the CEO's discussion during the Company's most recent conference call.
That being said, this situation still remains a speculation and quite a bit of a long shot. However, at these low prices, I am "in" with a small investment position that reflects the nature of the gamble.